Breast Cancer Now media statements

Breast Cancer Now responds to latest NHSE Cancer Wait Times data, calling for the FDS to be raised to 95%

Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to the latest NHS England cancer waiting times data, calling for the Faster Diagnosis Standard to be raised to 95%.

13 Oct 2022

Fantastic outcome for certain patients with incurable secondary triple negative breast cancer as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said that the approval of pembrolizumab (Keytruda) in combination with chemo for use on the NHS in Scotland was fantastic news.

10 Oct 2022

Pembrolizumab in combination with chemo is approved for use on the NHS in Scotland

Breast Cancer Now hails a fantastic outcome for certain patients with incurable secondary triple negative breast cancer, as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland.

10 Oct 2022

We welcome approval of palbociclib with fulvestrant for routine use on the NHS

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said the approval of palbociclib with fulvestrant for routine use on the NHS was absolutely fantastic news for breast cancer patients.

23 Sept 2022

We respond to research about breast cancer surgery margins

Jane Murphy, Senior Clinical Nurse Specialist at Breast Cancer Now, responded to new research about breast cancer surgery margins.

22 Sept 2022

We respond to research about physical activity and breast cancer risk

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, commented on new research about the relationship between physical activity and breast cancer risk.

07 Sept 2022

Breast Cancer Now responds to the HSJ and BBC Newsnight's joint special investigation about long cancer waits

Internal NHS data seen by the Health Service Journal (HSJ) and BBC Newsnight has revealed that "the number of patients waiting three months or longer, following referral for suspected cancer, remains at just over 10,000 patients last month". Here is the response of Baroness Delyth Morgan, Chief Executive at Breast Cancer Now.

11 Aug 2022

We respond to MP Dawn Butler's mission to find the Million Missing Mammograms

02 Aug 2022

Breast Cancer Now welcomes NICE decision to recommend alpelisib with fulvestrant for routine use on the NHS

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said it was fantastic news that alpelisib with fulvestrant has now been recommended by the National Institute for Health and Care Excellence (NICE) for routine use on the NHS.

14 Jul 2022

Breast Cancer Now celebrates landmark victory as Trodelvy is recommended for use on the NHS in England

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, has expressed her excitement that Trodelvy has finally been recommended by the National Institute for Health and Care Excellence (NICE) for use on the NHS in England.

14 Jul 2022

We respond to the approval of breast cancer drug abemaciclib for routine use on the NHS

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, expressed his excitement about the approval of breast cancer drug abemaciclib for routine use on the NHS.

17 Jun 2022

We respond to research that suggests drugs that neutralise progesterone activity could be a potential risk-reducing treatment for women with altered BRCA genes

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said the findings were exciting.

15 Jun 2022